Shire Overstates Benefits of Attention Deficit Drug Intuniv, US FDA Says Bloomberg The Dublin-based company has been betting on Intuniv and Vyvanse, the successor to Shire's Adderall treatment for hyperactivity, to counter losses after ... and more »

April 29 (Bloomberg) -- Shire Plc’s first-quarter profit fell less than analysts estimated as higher sales of the Replagal medicine for a rare illness helped make up for a plunge in revenue from the Adderall XR hyperactivity pill.

Shire First-Quarter Profit Falls Less Than Forecast Bloomberg Sales of Vyvanse, the company's successor to Adderall, rose 32 percent to $154 million. Genzyme's Allston Landing plant was closed in June after infection ...

April 29 (Bloomberg) -- Shire Plc ’s first-quarter profit fell less than analysts estimated as higher sales of the Replagal medicine for a rare illness helped make up for a plunge in revenue from the Adderall XR hyperactivity pill. (Corrects Adderall sales in third paragraph.) April 29 (Bloomberg) -- Shire Plc said first-quarter profit fell 22 percent as a flood of generic competition to the drugmaker’s Adderall XR hyperactivity pill eroded sales.